从行业市盈率排名来看，公司所处的物流行业行业市盈率平均24.60倍，行业中值23.53倍，华贸物流排 名第27位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)27华贸物流17.1815.621.3884.17亿行业平均 24.6027.051.88168.81亿行业中值23.5324.761.6649.49亿1瑞茂通-1732.6871.800.6047.81亿2飞力达-422.40- 295.892.4134.74亿3胜通能源-403.51-158.981.7926.85亿4华鹏飞-114.83197.703.7133.89亿5普路通-90.67- 34.082.4528.82亿6中科微至-53.90-44.091.0637.36亿7长江投资-38.49-40.0321.8429.99亿8新宁物流-33.66- 30.0810.5921.89亿9*ST原尚-24.72-27.362.5514.60亿10龙洲股份-6.78-7.552.3326.32亿11东航物流 7.857.731.15207.65亿 截至2025年一季报，共有7家机构持仓华贸物流，其中其他2家、社保2家、基金2家、保险1家，合 ...

Group 1 - The core viewpoint of the articles highlights Huaneng International's current stock performance, with a closing price of 7.4 yuan and a rolling PE ratio of 11.05 times, significantly lower than the industry average of 23.46 times [1][2] - Huaneng International's total market capitalization is reported at 116.166 billion yuan, ranking 14th in the electricity sector based on PE ratio [1][2] - The company has a total of 106,310 shareholders as of March 31, 2016, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Huaneng International's main business involves power generation and sales, with additional services in port and transportation [1] - The latest quarterly report for Q1 2025 shows a revenue of 60.335 billion yuan, a year-on-year decrease of 7.70%, while net profit increased by 8.19% to 4.973 billion yuan, with a gross margin of 19.05% [1] - The company holds a total of 2,021 patents, including 1,021 invention patents, 746 utility model patents, and 316 international patents [1]

Group 1 - The core viewpoint of the news is that Aide Biological's stock is underperforming compared to its industry peers, with a current PE ratio of 28.21, significantly lower than the industry average of 48.71 [1][2] - Aide Biological's market capitalization is reported at 7.932 billion yuan, ranking 65th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 9.8921 million yuan in principal funds on May 22, with a total outflow of 8.7322 million yuan over the past five days [1] Group 2 - Aide Biological specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - For the first quarter of 2025, Aide Biological reported revenue of 272 million yuan, a year-on-year increase of 16.63%, and a net profit of 90.4718 million yuan, reflecting a year-on-year growth of 40.92% [1] - The company's gross profit margin stands at 83.48% [1]

5月21日，菱电电控今日收盘55.58元，下跌3.02%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到87.15倍，总市值28.80亿元。 武汉菱电汽车电控系统股份有限公司的主营业务是发动机管理系统、纯电动汽车动力电子控制系统、混 合动力汽车动力电子控制系统、车联网产品以及相关的技术开发及标定服务。公司的主要产品是汽油 EMS、混合动力EMS、两用燃料（汽油、CNG）汽车EMS、摩托车EMS、电机控制器、发电机控制 器、整车控制器、T-BOX、电机电控二合一、HECU、四合一电机控制器、PCU、GECU发电三合一、 动力车身域控制器。 最新一期业绩显示，2025年一季报，公司实现营业收入3.12亿元，同比21.55%；净利润1747.60万元， 同比4521.16%，销售毛利率18.59%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)193菱电电控87.15180.591.7528.80亿行业平均 43.4046.303.7787.09亿行业中值36.5938.683.0749.24亿1长春一东-2985.83-1279.096.3829.69亿2圣龙股 份-2302.60157. ...

5月20日，爱迪特今日收盘56.11元，上涨2.99%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到26.95倍，创31天以来新低，总市值42.71亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，爱迪特排名 第59位。 资金流向方面，5月20日，爱迪特主力资金净流出35.11万元，近5日总体呈流出状态，5日共流出174.90 万元。 爱迪特(秦皇岛)科技股份有限公司的主营业务是口腔修复材料的研发、生产和销售；口腔数字化设备的 设计和销售。公司的主要产品是口腔修复材料、口腔数字化设备。 最新一期业绩显示，2025年一季报，公司实现营业收入2.05亿元，同比18.07%；净利润3127.14万元， 同比34.21%，销售毛利率51.00%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)59爱迪特26.9528.382.1242.71亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.96 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhenghai Biological, which closed at 20.38 yuan, with a PE ratio of 30.35, marking a new low in 23 days, and a total market capitalization of 3.668 billion yuan [1] - Zhenghai Biological ranks 67th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1] - As of March 31, 2025, Zhenghai Biological had 16,966 shareholders, a decrease of 193 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business of Zhenghai Biological involves the research, production, and sales of bio-regenerative materials, including oral repair membranes, absorbable dura mater patches, bone repair materials, and surgical sponges [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023, as announced by the Shandong Provincial Department of Industry and Information Technology [1] - In the latest quarterly report for Q1 2025, Zhenghai Biological reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, and a net profit of 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

资金流向方面，5月20日，透景生命主力资金净流出337.53万元，近5日总体呈流入状态，5日共流入 166.88万元。 上海透景生命科技股份有限公司的主营业务是自主品牌的体外诊断产品的研发、生产和销售。公司的主 要产品是体外诊断试剂、体外诊断仪器、服务收入。公司积极参与各类健康主题公益活动，比如全国三 八妇女节公益活动、全国子宫颈癌和乳腺癌防治咨询公益活动等，践行社会担当，并连续多年荣获中国 癌症基金会颁发的"社会公益奖"等多项奖项，积极履行社会责任。 5月20日，透景生命今日收盘14.12元，上涨1.58%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到58.28倍，创30天以来新低，总市值23.02亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入7489.31万元，同比-19.53%；净利润47.17万元， 同比110.51%，销售毛利率63.66%。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，透景生命排 名第92位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)92透景生命58.2866.651.5323.02亿行业平均 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)110冠昊生物127.86130.086.4035.66亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732.2888.97亿4爱朋医疗-370.37281.374.4630.39亿5博晖 创新-330.72524.813.5348.52亿6硕世生物-137.27-2005.841.2340.15亿7奥精医疗-130.15-190.761.7224.15亿 8睿昂基因-105.86-86.911.5013.70亿9康泰医学-86.99-73.503.1057.26亿10中红医疗-73.12-58.330.9350.82亿 11华大智造-58.05-51.514.00309.51亿 冠昊生物科技股份有限公司的主营业务是致力于开发具有自主知识产权的新产品、新技术,将提升产品 质量、优化产品结构视为企业发展的核心驱动力,积极应对市场挑战,不断调整优化营销策略 ...

四川港通医疗设备集团股份有限公司的主营业务是医用气体装备及系统、医用洁净装备及系统的研发、 设计、制造、集成及运维服务。公司的主要产品是医用气体装备及系统、医用洁净装备及系统、医疗设 备及其他产品销售、运维服务。公司先后被评为"国家级专精特新小巨人企业""国家级高新技术企 业""四川省行业小巨人企业""中国气体行业领军企业""全国医用气体优秀工程企业""中国医用气体装备 创新基地""全国医用气体从业人员培训基地"。 最新一期业绩显示，2025年一季报，公司实现营业收入2428.67万元，同比-68.09%；净利润157.90万 元，同比-85.25%，销售毛利率36.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)120港通医疗366.87134.661.5619.42亿行业平均 49.2647.464.56105.99亿行业中值36.7137.322.4947.70亿1天益医疗-1763.34-3020.401.8822.47亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-411.11-486.242.2687.98亿4爱朋医疗-367.45279.154.4330.1 ...

江苏宝利国际投资股份有限公司的主营业务是通用型改性沥青、高强度结构沥青料、高铁专用乳化沥 青、废橡塑改性沥青等专业沥青产品的生产销售；直升机及航材的销售业务；BT项目投资业务。公司 的主要产品是道路石油沥青、通用改性沥青、飞行器租售及运营。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比-42.82%；净利润323.90万元，同 比-26.61%，销售毛利率1.83%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)154宝利国际170.55161.573.7236.03亿行业平均 43.8351.703.9978.70亿行业中值39.3439.752.3041.51亿1渝三峡A-3559.771297.744.5556.67亿2锦鸡股 份-404.94603.002.0134.08亿3安诺其-332.58-1357.232.5464.41亿4信德新材-257.22-108.321.3335.79亿5石 大胜华-178.65433.141.8371.12亿6鼎际得-174.30-283.162.1834.35亿7富淼科技-151.24-421.471.4619.62亿8 达威股 ...